Key Points

South Korea's drug side effects compensation program experienced its first decline in six years during 2024. The government collected 4.75 billion won from pharmaceutical companies but paid out only 1.84 billion won in compensation. Experts suggest the decline stems from reduced death-related payouts and limited public awareness of the relief program. The government is now considering more active promotion through medical channels to increase program visibility.

Key Points: South Korea Drug Side Effects Compensation Drops in 2024

  • Compensation drops to 1.84 billion won in 2024
  • Government collected 4.75 billion won from pharma companies
  • Relief program supports victims of adverse drug reactions
  • Low public awareness impacts payouts
2 min read

South Korea: Compensation for drug side effects falls for 1st time in 6 yrs

South Korea sees first decline in drug side effects compensation in 6 years, with payouts falling 18.3% amid low program awareness.

"As payouts accounted for only 38.7 percent of the funds collected last year, the government should more actively promote the program - Industry Official"

Seoul, May 25

The amount of compensation paid to victims of drug side effects in South Korea declined in 2024 for the first time in six years, government data showed on Sunday.

The government collected 4.75 billion won (US$3.5 million) last year from 760 pharmaceutical companies for the national drug side effects relief fund, according to the Ministry of Food and Drug Safety and the Korea Institute of Drug Safety & Risk Management.

The relief program provides financial support to individuals or bereaved families of those who suffer death, disability or illness caused by adverse drug reactions, reports Yonhap news agency.

Financial assistance includes lump-sum payments for death or disability, medical expenses and funeral costs.

In 2024, compensation was paid out for 161 cases, reaching 1.84 billion won, down 18.3 percent from 2.25 billion won a year earlier, the data showed.

The decline is mainly due to a decrease in compensation for deaths linked to side effects and lack of public awareness of the program.

"As payouts accounted for only 38.7 percent of the funds collected last year, the government should more actively promote the program through hospitals, medical professionals and pharmacies," an industry official said.

Meanwhile, South Korea will work to triple the size of the animal medicine market to 4 trillion won (US$2.7 billion) by 2035 as part of efforts to foster new growth engines for the economy, the agriculture ministry said last month.

The government also aims to increase the country's exports of veterinary medicine products fivefold to 1.5 trillion won and create 15 animal pharmaceutical companies with an annual revenue of at least 50 billion won each over the next 10 years, according to the Ministry of Agriculture, Food and Rural Affairs.

The ministry said the plan comes amid growing demand for animal pharmaceutical products around the globe, sparked by an increase in pet ownership, livestock product consumption and infectious diseases in animals.

- IANS

Share this article:

Reader Comments

R
Rahul K.
Interesting to see South Korea's approach to drug safety. In India, we need similar robust systems for pharmaceutical compensation. Our generic drug industry is massive but patient safety mechanisms need strengthening. 🇮🇳
P
Priya M.
The decrease in compensation payouts is concerning. If public awareness is low, many victims might be suffering without support. Korean government should collaborate with NGOs for better outreach. India could learn from both their successes and shortcomings.
A
Arjun S.
Meanwhile, India's pharmaceutical industry is growing at 15% annually! We export medicines to over 200 countries including South Korea. But yes, we must also focus on patient safety and compensation systems like this. Jai Hind!
S
Sneha R.
The animal medicine market expansion plan is visionary 🐕. With India's traditional Ayurveda and growing pet care industry, we could explore similar opportunities. Maybe India-South Korea collaboration in this sector?
V
Vikram P.
While the compensation system is good, 38.7% fund utilization shows inefficiency. Indian bureaucracy faces similar challenges - great policies but poor implementation. Hope they fix this soon.
N
Neha T.
As someone whose family member suffered from drug side effects, I appreciate such systems. India should implement mandatory compensation funds from pharma companies. Patient lives matter more than profits.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50